New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26
Portfolio Pulse from
The InsiGHTS trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome achieved its primary objective at Week 26, demonstrating a safety and tolerability profile comparable to daily somatropin across all starting dose cohorts.
December 16, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ascendis Pharma's InsiGHTS trial for TransCon™ hGH in Turner Syndrome met its primary objective, showing safety and tolerability similar to daily somatropin.
The successful achievement of the primary objective in the InsiGHTS trial is a positive development for Ascendis Pharma, as it demonstrates the potential of TransCon™ hGH in a new indication outside of growth hormone deficiency. This could lead to expanded market opportunities and increased investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90